Definium Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell DFTX and other ETFs, options, and stocks.

About DFTX

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. 

CEO
Robert Barrow
CEORobert Barrow
Employees
74
Employees74
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
2010
Founded2010
Employees
74
Employees74

DFTX Key Statistics

Market cap
1.65B
Market cap1.65B
Price-Earnings ratio
-8.51
Price-Earnings ratio-8.51
Dividend yield
Dividend yield
Average volume
2.37M
Average volume2.37M
High today
$17.14
High today$17.14
Low today
$14.62
Low today$14.62
Open price
$14.64
Open price$14.64
Volume
3.68M
Volume3.68M
52 Week high
$17.14
52 Week high$17.14
52 Week low
$4.70
52 Week low$4.70

Stock Snapshot

With a market cap of 1.65B, Definium Therapeutics(DFTX) trades at $16.88. The stock has a price-to-earnings ratio of -8.51.

As of 2026-01-21, Definium Therapeutics(DFTX) stock has fluctuated between $14.62 and $17.14. The current price stands at $16.88, placing the stock +15.5% above today's low and -1.5% off the high.

The Definium Therapeutics(DFTX)'s current trading volume is 3.68M, compared to an average daily volume of 2.37M.

During the past year, Definium Therapeutics(DFTX) stock moved between $4.70 at its lowest and $17.14 at its peak.

During the past year, Definium Therapeutics(DFTX) stock moved between $4.70 at its lowest and $17.14 at its peak.

Analyst ratings

100%

of 13 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own DFTX. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the .